Showing 3291-3300 of 5646 results for "".
- FDA Clamps Down On At-Home Coronavirus Testing, Citing Fake Products and Bad Actorshttps://modernod.com/news/fda-clamps-down-on-at-home-coronavirus-testing-citing-fake-products-and-bad-actors/2477444/After telling companies, laboratories and state health departments to move forward with emergency coronavirus testing without federal oversight or approval, the FDA is now working to rein in the ones it describes as going too far, according to a <
- Adaptive Biotechnologies and Microsoft Expand Partnership to Decode COVID-19 Immune Response and Provide Open Data Accesshttps://modernod.com/news/adaptive-biotechnologies-and-microsoft-expand-partnership-to-decode-covid-19-immune-response-and-provide-open-data-access/2477435/Adaptive Biotechnologies and Microsoft announced they will leverage their existing partnership mapping population-wide adaptive immune responses to diseases at scale to study COVID-19. Finding the relevant immune response signature may advance solutions to diagnose, treat and prevent the disease,
- New Podcast Addresses COVID-19 Impacthttps://modernod.com/news/new-podcast-addresses-covid-19-impact/2477431/In the latest installment of the Off the Grid podcast, titled “Unprecedented Times,” cohosts Gary Wörtz, MD, and Blake Williamson, MD, MPH, speak with Steven J. Dell, MD, and Tal Raviv, MD, to discuss the novel coronavirus and its impact on their respective states, practices, and dail
- President of Glaucoma Research Foundation Issues Messagehttps://modernod.com/news/president-of-glaucoma-research-foundation-issues-message/2477429/The Glaucoma Research Foundation sent an email to its membership on Friday, answering questions that glaucoma specialists may have during the COVID-19 pandemic. The letter reads: Dear Friends, Your health and well-being are on our minds as we all deal with a national and glob
- Everads Therapy Enters Into Option Agreement to License Suprachoroidal Delivery System for Retinal Diseasehttps://modernod.com/news/everads-therapy-enters-into-option-agreement-to-license-suprachoroidal-delivery-system-for-retinal-disease/2477376/Everads Therapy announced that it has signed an option agreement with a large global pharmaceutical company, which will support the potential of its technology to overcome certain risks and side effects associated with current retinal disease treatment options, according to a company news release
- New Automated Method Developed for Corneal Nerve Fiber Tortuosity Analysishttps://modernod.com/news/new-automated-method-developed-for-corneal-nerve-fiber-tortuosity-analysis/2477369/The Intelligent Medical Imaging (iMED) Group at the Cixi Institute of Biomedical Engineering, Ningbo Institute of Materials Technology and Engineering (CNITECH) of the Chinese Academy of Sciences proposed a fully automated method for image-level corneal nerve fiber tortuosity estimation, contribu
- Nicox’s End-of-Phase 2 Meeting With the FDA Sets Stage for NCX 470 Phase 3 Program in Glaucomahttps://modernod.com/news/nicoxs-end-of-phase-2-meeting-with-the-fda-sets-stage-for-ncx-470-phase-3-program-in-glaucoma/2477350/Nicox announced that it has successfully completed an end-of-phase 2 meeting with the FDA and agreed on the design for the NCX 470 phase 3 program, as well as nonclinical and CMC plans supporting submission of a new drug application (NDA) in the U.S. NCX 470, a novel second generation nitric oxid
- Graybug Vision Presents Preclinical Results for Glaucoma Drug Candidate GB-401https://modernod.com/news/graybug-vision-presents-preclinical-results-for-glaucoma-drug-candidate-gb-401/2477332/Graybug Vision presented preclinical study results for GB-401, a novel injectable depot formulation of a proprietary beta-adrenergic antagonist prodrug, as a potential sustained-delivery treatment of up to 6 months for primary open angle glaucoma (POAG), at the American Glaucoma Society annual me
- AbbVie-Allergan Deal Foes Try Again to Spur an FTC Crackdownhttps://modernod.com/news/abbvie-allergan-deal-foes-try-again-to-spur-an-ftc-crackdown/2477311/AbbVie and Allergan’s megamerger is likely in the final stages of review after the pair agreed to offload three drugs, including IL-23 hopeful brazikumab. But a cadre of union and consumer groups say that’s not enough—and they’re taking another stab at turning regulators against
- Ribomic Announces First Injection in the Phase 2 Clinical Trial of RBM-007 (TOFU Study) in Subjects with Wet AMDhttps://modernod.com/news/ribomic-announces-first-injection-in-the-phase-2-clinical-trial-of-rbm-007-tofu-study-in-subjects-with-wet-amd/2477304/Ribomic announced that first patient has received injection in the phase 2 trial of RBM-007 for the treatment of wet age-related macular degeneration (AMD) in the United States. The first site started enrollment at the end of December 2019 and five sites are now active across the United States.</